Search
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalIt was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. … Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnIt was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow.
Sodium citrate
go.drugbank.com/drugs/DB09154ApprovedInvestigationalIt works by neutralizing excess acid in the blood and urine. It has been indicated for the treatment of metabolic acidosis.
Citric acid
go.drugbank.com/drugs/DB04272ApprovedInvestigationalNutraceuticalVet approvedCitric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.
Typhoid Vi polysaccharide vaccine
go.drugbank.com/drugs/DB10803ApprovedInvestigationalIt is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalNeisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalIt is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Faropenem medoxomil
go.drugbank.com/drugs/DB05659InvestigationalIt is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.
Alkaline Phosphatase
go.drugbank.com/drugs/DB05768InvestigationalAP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
Sitimagene ceradenovec
go.drugbank.com/drugs/DB04907ExperimentalIt is being developed by Ark Therapeutics.